XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.23.1

EARNINGS (LOSS) PER SHARE | 3 Months Ended
--- | ---
Mar. 31, 2023
Earnings Per Share [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS (LOSS) PER SHARE Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:
|  |  | Three Months Ended March 31,
(in millions, except per share amounts) |  |  |  |  | 2023 |  | 2022
Net loss attributable to Bausch Health Companies Inc. |  |  |  |  | $ | (201) |  |  | $ | (69) |
Basic and diluted weighted-average common shares outstanding |  |  |  |  | 363.3 |  |  | 360.8 |
Basic and diluted loss per share attributable to Bausch Health Companies Inc. |  |  |  |  | $ | (0.55) |  |  | $ | (0.19) |
During the three months ended March 31, 2023 and 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,426,000 and 3,600,000 common shares for the three months ended March 31, 2023 and 2022, respectively.During the three months ended March 31, 2023 and 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 17,636,000 and 9,332,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended March 31, 2023 and 2022, an additional 90,000 and 156,000 performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration